HY-16561-200mg | Resveratrol [501-36-0] Clinisciences

Descripciòn

Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator^[1]^[2]^[3]^[4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor^[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model^[6]. Resveratrol increases production of NO in endothelial cells^[7].

IC₅₀ & Target^[1]

Adenylyl cyclase

0.8 nM (IC₅₀)

IKKβ

1 μM (IC₅₀)

DNA polymerase α

3.3 μM (IC₅₀)

DNA polymerase δ

5 μM (IC₅₀)

Autophagy

Mitophagy

Sirtuin

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	31.4 μM Compound: resveratrol	Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining	[PMID: 19757853]
518A2	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
A253 cell line	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	48 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A2780 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay Anticancer activity against human A2780 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay	[PMID: 32485531]
A2780	IC₅₀	65 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A2780 cells assessed as cell growth inhibition by LDH release assay Anticancer activity against human A2780 cells assessed as cell growth inhibition by LDH release assay	[PMID: 32485531]
A2780	IC₅₀	74 μM Compound: 5	Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay	[PMID: 24239390]
A-431	IC₅₀	49.4 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A-431 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 32485531]
A549	IC₅₀	> 100 μM Compound: Resveratrol	Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
A549	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	10.5 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
A549	IC₅₀	119.6 μM Compound: Res, Resveratrol	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 21920747]
A549	IC₅₀	16 μM Compound: Resv	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
A549	IC₅₀	30.4 μg/mL Compound: RES	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 21440448]
A549	IC₅₀	44.7 pM Compound: 1, RSV, Resveratrol	Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21851083]
A549	CC₅₀	52.6 μM Compound: Resveratrol	Cytotoxicity against human A549 cells assessed as reduction in cell viability by Alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by Alamar blue assay	[PMID: 32652408]
A549	IC₅₀	66.25 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
ASPC1	IC₅₀	24.96 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human ASPC1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human ASPC1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32485531]
B16	IC₅₀	14.35 μg/mL Compound: Resveratrol	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 18586355]
B16-F10	IC₅₀	> 200 μM Compound: 1, Resveratrol	Cytotoxicity against mouse B16F10 cells assessed as suppression of cell viability after 72 hrs Cytotoxicity against mouse B16F10 cells assessed as suppression of cell viability after 72 hrs	[PMID: 22189272]
B16-F10	IC₅₀	37.3 μg/mL Compound: RES	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 21440448]
Bel-7402	IC₅₀	139.03 μM Compound: Res	Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
Bel-7402	IC₅₀	50.7 μM Compound: Resveratrol	Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
BV-2	IC₅₀	10.32 μM Compound: Res	Anti-neuroinflammation in mouse BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess reagent based assay Anti-neuroinflammation in mouse BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess reagent based assay	[PMID: 33017743]
BV-2	IC₅₀	10.99 μM Compound: Resveratrol	Inhibition of NO production in LPS-induced mouse BV-2 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Inhibition of NO production in LPS-induced mouse BV-2 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 34752955]
BV-2	IC₅₀	11.1 μM Compound: Res	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation for 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation for 24 hrs by Griess assay	[PMID: 30771601]
BV-2	IC₅₀	11.1 μM Compound: Resveratrol	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay	[PMID: 29499485]
BV-2	IC₅₀	18.66 μM Compound: 30	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
BV-2	IC₅₀	8.7 μM Compound: Resveratrol	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA	[PMID: 29499485]
BV-2	IC₅₀	9.5 μM Compound: Resveratrol	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA	[PMID: 29499485]
BXPC-3	IC₅₀	14 μM Compound: Resv	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
BXPC-3	IC₅₀	27.98 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32485531]
BXPC-3	GI₅₀	3.3 μg/mL Compound: 1a	Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
BXPC-3	GI₅₀	3.3 μg/mL Compound: E-3	Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
C8166	CC₅₀	35.57 μg/mL Compound: Resveratrol	Cytotoxicity against human C8166 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32652408]
Caco-2	IC₅₀	190.2 μM Compound: RSV; 1, Trans-RSV	Anti cancer activity against human Caco-2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay Anti cancer activity against human Caco-2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay	[PMID: 32485531]
Caco-2	IC₅₀	24.35 μM Compound: 17, Resveratrol	Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
Capan-2	IC₅₀	26.49 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human Capan-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human Capan-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32485531]
CCRF-CEM	IC₅₀	0.9 μM Compound: Resveratrol	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
CCRF-CEM	IC₅₀	5.91 μg/mL Compound: Resveratrol	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 18586355]
CNE	IC₅₀	67.62 μM Compound: 1, resveratrol,(Res)	Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay	[PMID: 18952444]
CNE-2	IC₅₀	52.28 μM Compound: 1, resveratrol,(Res)	Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay	[PMID: 18952444]
COLO 201	IC₅₀	37 μM Compound: Resv	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
COLO 205	IC₅₀	23.5 μM Compound: Resveratrol	Antiproliferative activity against human COLO205 cells by MTT assay Antiproliferative activity against human COLO205 cells by MTT assay	[PMID: 25455486]
DLD-1	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
DLKP cell line	IC₅₀	10 μM Compound: 1	Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay	[PMID: 19481462]
DU-145	GI₅₀	3.5 μg/mL Compound: 1a	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
DU-145	GI₅₀	3.5 μg/mL Compound: E-3	Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
Fibroblast	IC₅₀	218 μM Compound: Resveratrol	Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
HaCaT	IC₅₀	18.31 μM Compound: Resveratrol	Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA	[PMID: 35172097]
HaCaT	IC₅₀	35.1 μM Compound: Trans-Resveratrol	Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA	[PMID: 34463498]
HaCaT	IC₅₀	85.2 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HaCaT cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human HaCaT cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 32485531]
HCT-116	IC₅₀	> 60 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HCT-116	IC₅₀	31 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 5 days by SRB assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 5 days by SRB assay	[PMID: 32485531]
HCT-116	IC₅₀	62.61 μM Compound: Res	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
HCT-8	IC₅₀	5.82 μg/mL Compound: Resveratrol	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 18586355]
HEK293	EC₅₀	> 30 μM Compound: 1	Agonist activity at human TRPA1 expressed in HEK293 cells assessed as induction of calcium influx at 30 uM after 6 mins by Fluo-4 dye-based assay Agonist activity at human TRPA1 expressed in HEK293 cells assessed as induction of calcium influx at 30 uM after 6 mins by Fluo-4 dye-based assay	[PMID: 28576617]
HEK293	IC₅₀	> 30 μM Compound: 1	Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced calcium influx preincubated for 6 mins followed by AITC addition measured for 1 min by Fluo-4 dye-based assay Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced calcium influx preincubated for 6 mins followed by AITC addition measured for 1 min by Fluo-4 dye-based assay	[PMID: 28576617]
HEK293	IC₅₀	0.173 μM Compound: 1, Resveratrol	Inhibition of TNF-alpha-induced NF-kappaB activity expressed in HEK293 cells after 48 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activity expressed in HEK293 cells after 48 hrs by luciferase reporter gene assay	[PMID: 20527891]
HEK293	IC₅₀	0.75 μM Compound: 1	Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced current response by whole cell patch clamp method Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced current response by whole cell patch clamp method	[PMID: 28576617]
HEK293	IC₅₀	0.98 μM Compound: 1	Inhibition of TNFalpha-induced NF-kappaB activity expressed in HEK293 cells by luciferase reporter gene assay Inhibition of TNFalpha-induced NF-kappaB activity expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 23142320]
HEK293	IC₅₀	0.98 μM Compound: 1	Inhibition of TNF-alpha activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay Inhibition of TNF-alpha activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 22386564]
HEK293	IC₅₀	0.98 μM Compound: trans-Resveratrol	Inhibition of TNFalpha-activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay Inhibition of TNFalpha-activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 22115839]
HEK293	IC₅₀	12 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HEK293 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Anticancer activity against human HEK293 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 32485531]
HEK293	IC₅₀	16.1 μM Compound: resveratrol	Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 18487053]
HEK293	IC₅₀	17 μM Compound: RTV	Growth inhibition of HEK293 cells after 2 days by MTT assay Growth inhibition of HEK293 cells after 2 days by MTT assay	[PMID: 28408224]
HEK293	IC₅₀	2.5 μM Compound: Resveratrol	Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay	[PMID: 24992702]
HEK293	IC₅₀	31 μM Compound: Resveratrol	Cytotoxicity against HEK293 cells after 3 days by MTT assay Cytotoxicity against HEK293 cells after 3 days by MTT assay	10.1039/C5MD00197H
HEK293	IC₅₀	7.1 μg/mL Compound: Resv.	Cytotoxicity against HEK293 cells assessed inhibition of cell proliferation after 2 days by MTT assay Cytotoxicity against HEK293 cells assessed inhibition of cell proliferation after 2 days by MTT assay	[PMID: 26402726]
HEK-293T	CC₅₀	22.75 μM Compound: Res	Cytotoxicity against HEK293T cells after 24 hrs by MTT assay Cytotoxicity against HEK293T cells after 24 hrs by MTT assay	[PMID: 29172079]
HeLa	IC₅₀	10.5 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
HeLa	IC₅₀	120.27 μM Compound: Res	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
HeLa	IC₅₀	152.4 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32485531]
HeLa	IC₅₀	22.5 pM Compound: 1, RSV, Resveratrol	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21851083]
HeLa	IC₅₀	47.9 μM Compound: Resveratrol	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
HeLa	IC₅₀	58.86 μM Compound: Resveratrol	Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
HeLa	IC₅₀	98.17 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
HepG2	IC₅₀	> 100 μM Compound: Resveratrol	Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
HepG2	IC₅₀	110.7 μM Compound: RSV; 1, Trans-RSV	Anti cancer activity against human HepG2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay Anti cancer activity against human HepG2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay	[PMID: 32485531]
HepG2	IC₅₀	354.8 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 32485531]
HepG2	IC₅₀	38.9 μg/mL Compound: RES	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21440448]
HepG2	EC₅₀	5.4 μM Compound: Resveratrol	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay	[PMID: 28126440]
HepG2	IC₅₀	50 μM Compound: resveratrol	Cytotoxicity against human HepG2 cells after 48 hrs by acid phosphatase method Cytotoxicity against human HepG2 cells after 48 hrs by acid phosphatase method	[PMID: 16252924]
HepG2	IC₅₀	54.9 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
HepG2	IC₅₀	79.6 μM Compound: Resveratrol	Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay	[PMID: 20346660]
HepG2	IC₅₀	80.3 μM Compound: RSV, Resveratrol	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 22326393]
HL-60	IC₅₀	2.45 μg/mL Compound: Resveratrol	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 18586355]
HL-60	IC₅₀	31.8 μM Compound: 4, (E)-resveratrol	Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
HL-60	IC₅₀	36.3 μM Compound: resveratrol	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 19251420]
HL-60	IC₅₀	64.1 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32485531]
HOS-TE85	IC₅₀	20.57 μM Compound: 29	Cytotoxicity against human MNNG/HOS cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MNNG/HOS cells incubated for 48 hrs by CCK-8 assay	[PMID: 33325699]
HT-144	IC₅₀	40 μM Compound: 1	Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay	[PMID: 19481462]
HT-22	EC₅₀	4667 nM Compound: Resveratrol	Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxytosis after 24 hrs by MTT assay Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxytosis after 24 hrs by MTT assay	[PMID: 21129978]
HT-29	IC₅₀	> 100 μM Compound: RES	Growth inhibition of human HT-29 cells after 48 hrs by MTT assay Growth inhibition of human HT-29 cells after 48 hrs by MTT assay	[PMID: 27783972]
HT-29	IC₅₀	> 60 μM Compound: 1	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HT-29	IC₅₀	110 μM Compound: Resveratrol	Antiproliferative activity against human HT-29 cells after 3 days by MTT assay Antiproliferative activity against human HT-29 cells after 3 days by MTT assay	[PMID: 23623255]
HT-29	IC₅₀	1115.9 μM Compound: RSV; 1, Trans-RSV	Anti cancer activity against human HT-29 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay Anti cancer activity against human HT-29 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay	[PMID: 32485531]
HT-29	IC₅₀	120 μM Compound: Resveratrol	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
HT-29	IC₅₀	130 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
HT-29	IC₅₀	137 μM Compound: RTV	Growth inhibition of human HT-29 cells after 2 days by MTT assay Growth inhibition of human HT-29 cells after 2 days by MTT assay	[PMID: 28408224]
HT-29	IC₅₀	150 μM Compound: Resveratrol	Cytotoxicity against human HT-29 cells after 3 days by MTT assay Cytotoxicity against human HT-29 cells after 3 days by MTT assay	10.1039/C5MD00197H
HT-29	IC₅₀	27 μM Compound: Resv	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HT-29	IC₅₀	34.1 μg/mL Compound: Resv.	Cytotoxicity against human HT-29 cells assessed inhibition of cell proliferation after 2 days by MTT assay Cytotoxicity against human HT-29 cells assessed inhibition of cell proliferation after 2 days by MTT assay	[PMID: 26402726]
HT-29	IC₅₀	45.3 μM Compound: 17, Resveratrol	Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
HT-29	IC₅₀	70 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 32485531]
HT-29	IC₅₀	87.2 μM Compound: Resveratrol	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 25455486]
Huh-7	IC₅₀	10.6 μM Compound: Resveratrol	Cytotoxicity against human Huh7.5.1 cells after 72 hrs Cytotoxicity against human Huh7.5.1 cells after 72 hrs	[PMID: 23673225]
J774	IC₅₀	12.15 μM Compound: 3	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 29726680]
J774	IC₅₀	13.6 μM Compound: 3	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA	[PMID: 29726680]
J774	IC₅₀	6.8 μM Compound: 3	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA	[PMID: 29726680]
K562	IC₅₀	9.62 μg/mL Compound: Resveratrol	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 18586355]
KB	IC₅₀	82.8 μM Compound: 1, RES, resveratrol	Cytotoxicity against human KB cells after 48 hrs Cytotoxicity against human KB cells after 48 hrs	[PMID: 17000031]
KM-20L2	GI₅₀	13.1 μg/mL Compound: 1a	Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
KM-20L2	GI₅₀	13.1 μg/mL Compound: E-3	Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
L02	IC₅₀	98.6 μM Compound: Res	Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
LLC-PK1	IC₅₀	52.5 μM Compound: 4, (E)-resveratrol	Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
LN-229	IC₅₀	11 μM Compound: Resv	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LoVo	IC₅₀	55 μM Compound: 56	Antiproliferative activity against human LoVo cells assessed as decrease in cell viability by MTT assay Antiproliferative activity against human LoVo cells assessed as decrease in cell viability by MTT assay	[PMID: 33445154]
MCF-10A	IC₅₀	> 100 μM Compound: RSV; 1, Trans-RSV	Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
MCF-12A	IC₅₀	93.5 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF-12A cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human MCF-12A cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 32485531]
MCF7	IC₅₀	> 100 μM Compound: Resveratrol	Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
MCF7	IC₅₀	> 100 μM Compound: Resveratrol	Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 23313635]
MCF7	IC₅₀	> 30 μM Compound: 22	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
MCF7	IC₅₀	> 30 μM Compound: resveratrol	Cytotoxicity against human MCF7 cells after 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs	[PMID: 10075742]
MCF7	IC₅₀	100 μM Compound: resveratrol	Cytotoxicity against human MCF7 cells after 48 hrs by acid phosphatase method Cytotoxicity against human MCF7 cells after 48 hrs by acid phosphatase method	[PMID: 16252924]
MCF7	IC₅₀	127 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 32485531]
MCF7	IC₅₀	135 μM Compound: Resveratrol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
MCF7	IC₅₀	16.1 μg/mL Compound: Resv.	Cytotoxicity against human MCF7 cells assessed inhibition of cell proliferation after 2 days by MTT assay Cytotoxicity against human MCF7 cells assessed inhibition of cell proliferation after 2 days by MTT assay	[PMID: 26402726]
MCF7	IC₅₀	19 μM Compound: resveratrol	Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs	[PMID: 10075742]
MCF7	IC₅₀	22.9 μM Compound: RES	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30053783]
MCF7	IC₅₀	24.6 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay	[PMID: 32485531]
MCF7	IC₅₀	25.4 μM Compound: RES	Antiproliferative activity against human MCF7 cells after 72 hrs in presence of OBHS by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs in presence of OBHS by MTT assay	[PMID: 30053783]
MCF7	IC₅₀	28.07 μM Compound: RSV, resveratrol	Cytotoxicity against human estrogen receptor positive MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human estrogen receptor positive MCF7 cells after 72 hrs by MTT assay	[PMID: 23860590]
MCF7	GI₅₀	3.9 μg/mL Compound: 1a	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
MCF7	GI₅₀	3.9 μg/mL Compound: E-3	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
MCF7	IC₅₀	34 μM Compound: RTV	Growth inhibition of human MCF7 cells after 2 days by MTT assay Growth inhibition of human MCF7 cells after 2 days by MTT assay	[PMID: 28408224]
MCF7	IC₅₀	40.49 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay	[PMID: 32485531]
MCF7	IC₅₀	61.71 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of Curcumin by MTS assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of Curcumin by MTS assay	[PMID: 32485531]
MCF7	IC₅₀	62 μM Compound: Resveratrol	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 26854376]
MCF7	IC₅₀	68.3 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition by CyQuant assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
MCF7	IC₅₀	71 μM Compound: Resveratrol	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	10.1039/C5MD00197H
MCF7	IC₅₀	79.1 pM Compound: 1, RSV, Resveratrol	Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21851083]
MCF7	IC₅₀	80 μM Compound: Resveratrol	Antitumor activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32942072]
MCF7	IC₅₀	85 μM Compound: Resveratrol	Inhibition of telomerase extracted from human MCF7 cells after 24 to 48 hrs by TRAP assay Inhibition of telomerase extracted from human MCF7 cells after 24 to 48 hrs by TRAP assay	10.1039/C0MD00241K
MCF7	IC₅₀	87.6 μM Compound: 1	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 22386564]
MCF7	IC₅₀	88.2 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
MDA-MB-231	IC₅₀	> 100 μM Compound: RES	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27783972]
MDA-MB-231	IC₅₀	129.9 μM Compound: resveratrol	Antiproliferative activity human MDA-MB-231 cells assessed as cell survival after 48 hrs by MTT assay Antiproliferative activity human MDA-MB-231 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 26344592]
MDA-MB-231	IC₅₀	15 μM Compound: Resv	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-231	IC₅₀	20.5 μM Compound: Resveratrol	Antitumor activity against human MDA-MB-231 cells after 6 days by SRB assay Antitumor activity against human MDA-MB-231 cells after 6 days by SRB assay	[PMID: 20728369]
MDA-MB-231	IC₅₀	40 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by CyQuant assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
MDA-MB-231	IC₅₀	57 μM Compound: Resveratrol	Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 26854376]
MDA-MB-231	IC₅₀	66 μM Compound: Resveratrol	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 23273518]
MDA-MB-231	IC₅₀	90.6 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
MDA-MB-231	IC₅₀	98.84 μM Compound: Resveratrol	Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay	[PMID: 34605238]
MDA-MB-435	IC₅₀	13.81 μg/mL Compound: Resveratrol	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 18586355]
MDA-MB-468	IC₅₀	45.2 μM Compound: Resveratrol	Antiproliferative activity against human MDA468 cells by MTT assay Antiproliferative activity against human MDA468 cells by MTT assay	[PMID: 25455486]
MDA-MB-468	IC₅₀	58 μM Compound: Resveratrol	Cytotoxicity against human MDA-MB-468 cells after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells after 96 hrs by MTT assay	[PMID: 26854376]
MG-63	IC₅₀	28.58 μM Compound: 29	Cytotoxicity against human MG-63 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MG-63 cells incubated for 48 hrs by CCK-8 assay	[PMID: 33325699]
MGC-803	IC₅₀	42 μM Compound: Resveratrol	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 25455486]
Microglia	IC₅₀	11.5 μM Compound: resveratrol	Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs	[PMID: 18588343]
MRC5	IC₅₀	56.6 μM Compound: 1; RES	Cytotoxicity against human MRC5 cells assessed as cellular metabolism incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cellular metabolism incubated for 72 hrs by MTT assay	[PMID: 35621995]
NCI-H460	IC₅₀	12 μM Compound: Resv	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NCI-H460	IC₅₀	12.9 μM Compound: 2	Antiproliferative activity against human H460 cells after 72 hrs Antiproliferative activity against human H460 cells after 72 hrs	[PMID: 20409723]
NCI-H460	GI₅₀	3.6 μg/mL Compound: 1a	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
NCI-H460	GI₅₀	3.6 μg/mL Compound: E-3	Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
NCI-H460	IC₅₀	58 μM Compound: Resveratrol	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
NIH3T3	IC₅₀	> 20 μM Compound: RSV; 1, Trans-RSV	Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition by CyQuant assay Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
NIH3T3	IC₅₀	> 24.2 μM Compound: 1, 17 trans-resveratrol	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay	[PMID: 21803587]
NIH3T3	IC₅₀	24.22 μM Compound: 22	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
OVCAR-3	IC₅₀	480 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay	[PMID: 32485531]
OVCAR-3	IC₅₀	525 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by LDH release assay Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by LDH release assay	[PMID: 32485531]
P388	ED₅₀	4.49 μg/mL Compound: E-3	Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
PANC-1	IC₅₀	39 μM Compound: Resv	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PANC-1	IC₅₀	70 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human PANC-1 cells assessed as cell growth inhibition by CyQuant assay Anticancer activity against human PANC-1 cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
PC-3	IC₅₀	3.51 μg/mL Compound: Resveratrol	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 18586355]
Ramos	IC₅₀	37 μM Compound: RTV	Growth inhibition of human Ramos cells after 2 days by MTT assay Growth inhibition of human Ramos cells after 2 days by MTT assay	[PMID: 28408224]
RAW	IC₅₀	15 μM Compound: 1, Resveratrol	Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 30 mins before LPS challenge measured after 20 hrs by Griess reaction method relative to control Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 30 mins before LPS challenge measured after 20 hrs by Griess reaction method relative to control	[PMID: 20527891]
RAW	IC₅₀	23.2 μM Compound: 1	Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method	[PMID: 23142320]
RAW264.7	IC₅₀	23.2 μM Compound: 1	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells after 18 hrs Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells after 18 hrs	[PMID: 22386564]
RAW264.7	IC₅₀	24.1 μg/mL Compound: 205	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay	[PMID: 31255927]
RAW264.7	IC₅₀	30.71 μM Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method	[PMID: 22386564]
RAW264.7	IC₅₀	30.71 μM Compound: trans-Resveratrol	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method	[PMID: 22115839]
RAW264.7	IC₅₀	44.1 μM Compound: 1a	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay	[PMID: 31350127]
SF-268	GI₅₀	4.1 μg/mL Compound: 1a	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 19719153]
SF-268	GI₅₀	4.1 μg/mL Compound: E-3	Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
SK-BR-3	IC₅₀	110.3 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32485531]
SK-BR-3	IC₅₀	41.42 μM Compound: RSV, resveratrol	Cytotoxicity against human estrogen receptor negative SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against human estrogen receptor negative SKBR3 cells after 72 hrs by MTT assay	[PMID: 23860590]
SK-MEL	IC₅₀	47.3 μM Compound: 4, (E)-resveratrol	Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SK-MEL-2	IC₅₀	14 μM Compound: Resv	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SK-N-SH	IC₅₀	40.3 pM Compound: 1, RSV, Resveratrol	Antiproliferative activity against human SK-N-SH cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human SK-N-SH cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21851083]
SK-OV-3	IC₅₀	113 μM Compound: 4, (E)-resveratrol	Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SK-OV-3	IC₅₀	29 μM Compound: Resveratrol	Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay	[PMID: 31514018]
SK-OV-3	IC₅₀	346 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition by LDH release assay Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition by LDH release assay	[PMID: 32485531]
SK-OV-3	IC₅₀	36.3 μM Compound: Resveratrol	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 31514018]
SK-OV-3	IC₅₀	380 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay	[PMID: 32485531]
SK-OV-3	IC₅₀	39.67 μM Compound: Resveratrol	Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay	[PMID: 31514018]
SK-OV-3	IC₅₀	47.98 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human SK-OV-3 assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human SK-OV-3 assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32485531]
SK-OV-3	IC₅₀	91.7 μM Compound: Resveratrol	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31514018]
SW480	IC₅₀	20 μM Compound: 1	Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs	[PMID: 20395019]
T47D	IC₅₀	25 μM Compound: Resv	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T47D	IC₅₀	59 μM Compound: Resveratrol	Cytotoxicity against human T47D cells after 96 hrs by MTT assay Cytotoxicity against human T47D cells after 96 hrs by MTT assay	[PMID: 26854376]
T47D	IC₅₀	76 μM Compound: Resveratrol	Cytotoxicity against human T47D cells by MTT assay Cytotoxicity against human T47D cells by MTT assay	[PMID: 23273518]
TOV112D	IC₅₀	10.67 μM Compound: Resveratrol	Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 31514018]
TOV112D	IC₅₀	11 μM Compound: Resveratrol	Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 31514018]
U-251	IC₅₀	> 50 μM Compound: RSV; 1, Trans-RSV	Anticancer activity against human U-251MG cells assessed as cell growth inhibition by CyQuant assay Anticancer activity against human U-251MG cells assessed as cell growth inhibition by CyQuant assay	[PMID: 32485531]
U373-MAGI	CC₅₀	> 400 μM Compound: Res	Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay	[PMID: 24120088]
U373-MAGI	EC₅₀	> 75 μM Compound: 1a	Antiviral activity against HIV1 infected in human U373-MAGI cells expressing CXCR4 assessed as inhibition of viral infection preincubated for 2 hrs prior to infection followed by compound wash out measured after 48 hrs by single round replication assay Antiviral activity against HIV1 infected in human U373-MAGI cells expressing CXCR4 assessed as inhibition of viral infection preincubated for 2 hrs prior to infection followed by compound wash out measured after 48 hrs by single round replication assay	[PMID: 23010273]
U373-MAGI	EC₅₀	10 μM Compound: Resveratrol	Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu	[PMID: 27117260]
U373-MAGI	CC₅₀	145 μM Compound: Resveratrol	Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM) Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)	[PMID: 27117260]
U373-MAGI	EC₅₀	99.6 μM Compound: Res	Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry	[PMID: 24120088]
U-87MG ATCC	IC₅₀	20 μM Compound: Resv	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-937	IC₅₀	17 μM Compound: resveratrol	Cytotoxicity against human U937 cells after 48 hrs by WST1 test Cytotoxicity against human U937 cells after 48 hrs by WST1 test	[PMID: 16252924]
Vero	IC₅₀	73.6 μM Compound: 4, (E)-resveratrol	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]

In Vitro

Resveratrol (trans-Resveratrol; SRT501) is one of the numerous polyphenolic compounds found in several vegetal sources In the vast majority of cases, Resveratrol displays inhibitory/activatory effects in the micromolar range, which is potentially attainable pharmacologically, although targets with affinities in the nanomolar range have also been reported^[1].
MCF-7 cells are plated in DME-F12 medium supplemented with 5% FBS in the presence of increasing concentrations of Resveratrol. Control cells are treated with the same volume of vehicle only (0.1% ethanol). Resveratrol inhibits the growth of MCF-7 cells in a dose-dependent fashion. Addition of 10 μM Resveratrol results in an 82% inhibition of MCF-7 cell growth after 6 days while at 1 μM, only a 10% inhibition is observed. The cells treated with 10 μM Resveratrol have a doubling time of 60 hr whereas control cells doubled every 30 hr. Trypan blue exclusion assay shows that at concentrations of 10 μM or lower, Resveratrol does not affect cell viability (90% viable cells) whereas at 100 μM, only 50% of the cells are viable after 6 days of Resveratrol treatment. Moreover, MCF-7 cells do not undergo apoptosis after incubation with Resveratrol at concentration of 10 μM as determined by ApoAlert Annexin V Apoptosis kit^[2].
Resveratrol increases the production of nitric oxide (NO) in endothelial cells by upregulating the expression of endothelial NO synthase (eNOS), stimulating eNOS enzymatic activity, and preventing eNOS uncoupling^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The average tumor volume is reduced by treatment with Resveratrol (trans-Resveratrol; SRT501) at a dose of 50 mg/kg body weight (195.5±124.8 mm³; P<0.05) or 100 mg/kg body weight (81.7±70.5 mm³; P<0.001) compare with the vehicle-treated animals (315±94 mm³). There is a good correlation between the tumor volume and the tumor mass^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

Peso molecular

228.24

Fòrmula

C₁₄H₁₂O₃

No. CAS

501-36-0

Appearance

Solid

Color

White to off-white

SMILES

OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1

Structure Classification

Phenols
Polyphenols

Initial Source

Plants
Vitaceae
Vitis vinifera cv. Zalema

Microorganisms

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (438.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.3814 mL	21.9068 mL	43.8135 mL
5 mM	0.8763 mL	4.3814 mL	8.7627 mL
10 mM	0.4381 mL	2.1907 mL	4.3814 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (21.91 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (21.91 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 5 mg/mL (21.91 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 6

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 7

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
Protocol 8

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 12.5 mg/mL (54.77 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 16.67 mg/mL (73.04 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.94%

Select Batch:

SDS (393 KB)

COA (245 KB) HNMR (247 KB) RP-HPLC (253 KB) LCMS (107 KB) Elemental Analysis Report (103 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Pirola L, et al. Resveratrol: one molecule, many targets. IUBMB Life. 2008 May;60(5):323-32. [Content Brief]

[2]. Lu R, et al. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 1999 Jun;179(3):297-304. [Content Brief]

[3]. Lee MH, et al. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res. 2009 Sep 15;69(18):7449-58. [Content Brief]

[4]. Du LL, et al. Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr). 2014 Apr;36(2):613-23. [Content Brief]

[5]. Smutny T, et al. Resveratrol as an inhibitor of pregnane X receptor (PXR): another lesson in PXR antagonism. J Pharmacol Sci. 2014;126(2):177-8. [Content Brief]

[6]. Eun Nim Kim,et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018 Jan; 10(1): 83–99. [Content Brief]

[7]. Huige Li, et al. Resveratrol and Vascular Function. Int J Mol Sci. 2019 Apr 30;20(9):2155. [Content Brief]

Ensayo celular ^[2]	To determine the effect of Resveratrol on cell growth, MCF-7 cells are plated in 6-well plates at 10⁵ cells per well in 2 mL of DME-F12 medium supplemented with 5% FBS in the presence or absence of increasing concentrations of Resveratrol. The cell number is measured every 2 days till day 6 with a hemocytometer after detaching the cells with trypsin-EDTA^[2]. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Administraciòn de animales ^[3]	Mice^[3] Female BALB/c (nu/nu) mice, 6 weeks old, are used. PA-1 cells (1×10⁷ in 200 μL PBS) are injected s.c. on the right hind flank. Tumor volume (length×width×depth×0.52) is measured three times a week. After 10 days of implantation, two groups (n=10) are given Resveratrol (dissolved in 5% ethanol and 25% polyethyleneglycol 400 in distilled water) i.p. at a daily dose of 50 or 100 mg/kg body weight for consecutive 4 weeks, whereas the other group receive the vehicle only. Body weights are recorded everyday. Animals are given bromodeoxyuridine (BrdUrd; 10 mg/kg body weight, i.p.) 2 h before sacrifice. Xenograft tumors are weighed and frozen in liquid nitrogen or fixed in 10% formalin and embedded in paraffin. The BrdUrd-labeled cells in paraffin-embedded tissues are detected employing a monoclonal anti-BrdUrd antibody. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Referencias	[1]. Pirola L, et al. Resveratrol: one molecule, many targets. IUBMB Life. 2008 May;60(5):323-32. [Content Brief] [2]. Lu R, et al. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 1999 Jun;179(3):297-304. [Content Brief] [3]. Lee MH, et al. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res. 2009 Sep 15;69(18):7449-58. [Content Brief] [4]. Du LL, et al. Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr). 2014 Apr;36(2):613-23. [Content Brief] [5]. Smutny T, et al. Resveratrol as an inhibitor of pregnane X receptor (PXR): another lesson in PXR antagonism. J Pharmacol Sci. 2014;126(2):177-8. [Content Brief] [6]. Eun Nim Kim,et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018 Jan; 10(1): 83–99. [Content Brief] [7]. Huige Li, et al. Resveratrol and Vascular Function. Int J Mol Sci. 2019 Apr 30;20(9):2155. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	4.3814 mL	21.9068 mL	43.8135 mL	109.5338 mL
	5 mM	0.8763 mL	4.3814 mL	8.7627 mL	21.9068 mL
	10 mM	0.4381 mL	2.1907 mL	4.3814 mL	10.9534 mL
	15 mM	0.2921 mL	1.4605 mL	2.9209 mL	7.3023 mL
	20 mM	0.2191 mL	1.0953 mL	2.1907 mL	5.4767 mL
	25 mM	0.1753 mL	0.8763 mL	1.7525 mL	4.3814 mL
	30 mM	0.1460 mL	0.7302 mL	1.4605 mL	3.6511 mL
	40 mM	0.1095 mL	0.5477 mL	1.0953 mL	2.7383 mL
	50 mM	0.0876 mL	0.4381 mL	0.8763 mL	2.1907 mL
	60 mM	0.0730 mL	0.3651 mL	0.7302 mL	1.8256 mL
	80 mM	0.0548 mL	0.2738 mL	0.5477 mL	1.3692 mL
	100 mM	0.0438 mL	0.2191 mL	0.4381 mL	1.0953 mL

Resveratrol Related Classifications

Inflammation/Immunology Infection Cancer
Cancer Targeted Therapy Cancer Immunotherapy Cancer Metabolism and Metastasis

NF-κB Autophagy Epigenetics Cell Cycle/DNA Damage Apoptosis Anti-infection
IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2

Resveratrol [501-36-0]

Referencia HY-16561-200mg

Contact local distributor :

Marca : MedChemExpress

Contact local distributor :

Other Forms of Resveratrol:

Ver todos los productos específicos de isoformas IKK:

Ver todos los productos específicos de isoformas Sirtuin:

Ver todos los productos específicos de isoformas Antibiotic:

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Resveratrol Related Classifications

Keywords:

Usted podría estar interesado también en los siguientes productos:

Resveratrol [501-36-0]

Referencia HY-16561-200mg

Contact local distributor :

Marca : MedChemExpress

Contact local distributor :

Other Forms of Resveratrol:

Ver todos los productos específicos de isoformas IKK:

Ver todos los productos específicos de isoformas Sirtuin:

Ver todos los productos específicos de isoformas Antibiotic:

Resveratrol Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Resveratrol Related Classifications

Keywords:

Usted podría estar interesado también en los siguientes productos: